Physician profile
Dixie Davidson Stone
NPI 1265443006
$4,631.65
in general payments reported to CMS, 2019-2025
37 companies · $1,650 in 2025
The $1,650 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $674 · 2022: $554 · 2023: $729 · 2024: $1,024 · 2025: $1,650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,168 · Consulting Fee: $175 · Education: $60.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,168.09 |
| Consulting Fee | $175.00 |
| Education | $60.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,042.11 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $511.77 | 2021-2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $315.85 | 2021-2025 | |
| Amgen INC. | $284.94 | 2022-2025 | Prolia, Repatha, Otezla |
| Teva Pharmaceuticals USA, INC. | $268.18 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $207.52 | 2023-2025 | Rexulti, Nuedexta |
| Astellas Pharma US INC | $185.35 | 2021-2024 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $166.62 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Axsome Therapeutics, INC. | $166.32 | 2024-2025 | Auvelity |
| Alkermes, INC. | $162.91 | 2023-2025 | Aristada, Lybalvi |
| Dexcom, INC. | $117.73 | 2021-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $117.41 | 2021-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $90.80 | 2021-2025 | Wegovy |
| Exact Sciences Corporation | $90.73 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $79.29 | 2022-2024 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dixie Stone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.